Integrated Filing — IndAS



General information about company
Scrip Code 532523
NSE Symbol BIOCON
MSEI Symbol NOTLISTED
ISIN INE376G01013
Name of company BIOCON LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 07-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 07-Aug-2025   18:15:00
End date and time of board meeting 07-Aug-2025   19:10:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 39419000000
Other income 797000000
Total income 40216000000
2 Expenses
(a) Cost of materials consumed 12240000000
(b) Purchases of stock-in-trade 8371000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -6560000000
(d) Employee benefit expense 8331000000
(e) Finance costs 2767000000
(f) Depreciation, depletion and amortisation expense 4550000000
(f) Other Expenses
1 Other Expenses 9894000000 9894000000
2 Recovery of cost from co-development partners (net) -346000000 -346000000
Total other expenses 9548000000
Total expenses 39247000000
3 Total profit before exceptional items and tax 969000000
4 Exceptional items 0
5 Total profit before tax 969000000
6 Tax expense
7 Current tax 667000000
8 Deferred tax -590000000
9 Total tax expenses 77000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 892000000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 892000000
17 Other comprehensive income net of taxes -2055000000
18 Total Comprehensive Income for the period -1163000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 314000000
Total profit or loss, attributable to non-controlling interests 578000000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent -1735000000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 572000000
21 Details of equity share capital
Paid-up equity share capital 6685000000
Face value of equity share capital 5
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.26
Diluted earnings (loss) per share from continuing operations 0.26
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.26
Diluted earnings (loss) per share from continuing and discontinued operations 0.26
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) tNotes:tttttttttt n n1.tThe unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 07, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. n n2.tThese financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. n n3.tThe consolidated financial results include the financial results of the Company and its subsidiaries as follows: n ni.tSyngene International Limited (‘’Syngene’’) nii.tBiocon Biologics Limited (“BBL”) niii.tBiocon Pharma Limited (“BPL”) niv.tBiocon Academy nv.tBiocon SA nvi.tBiocon SDN. BHD nvii.tBiocon FZ LLC nviii.tBiocon Biologics UK Limited nix.tBiocon Pharma Inc. nx.tBiocon Biologics Healthcare Malaysia SDN. BHD nxi.tBiocon Pharma Ireland Limited nxii.tBiocon Pharma UK Limited nxiii.tBiocon Biosphere Limited nxiv.tBiocon Biologics Inc. nxv.tBiocon Biologics Do Brasil Ltda nxvi.tBiocon Biologics FZ-LLC nxvii.tBiocon Pharma Malta Limited nxviii.tBiocon Pharma Malta I Limited nxix.tSyngene USA Inc. nxx.tSyngene Manufacturing Solutions Limited nxxi.tSyngene Scientific Solutions Limited nxxii.tBiosimilar Collaborations Ireland Limited nxxiii.tBiosimilars Newco Limited nxxiv.tBiocon Biologics Canada Inc. nxxv.tBiocon Biologics Germany GmbH nxxvi.tBiocon Biologics France S.A.S nxxvii.tBiocon Biologics Spain, S.L. nxxviii.tBiocon Biologics Switzerland AG nxxix.tBiocon Biologics Belgium BV nxxx.tBiocon Biologics Finland OY nxxxi.tBiocon Generics Inc. nxxxii.tBiocon Biologics Morocco S.A.R.L.A.U nxxxiii.tBiocon Biologics Greece SINGLE MEMBER P.C nxxxiv.tBiocon Biologics South Africa (PTY) Ltd nxxxv.tBiocon Biologics (Thailand) Co. Ltd nxxxvi.tBiocon Biologics Philippines Inc nxxxvii.tBiocon Biologics Italy S.R.L nxxxviii.tBiocon Biologics Croatia LLC nxxxix.tBiocon Biologics Global PLC n nBiocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. n n4.tDuring the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). n nOut of the above proceeds, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) of face value of Rs. 1,00,00,000 issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million. n n5.tOn May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- with record date of July 4, 2025. The proposed dividend is subject to the approval of the shareholders of the Company in its Annual General Meeting. n n6.tIn April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the quarter ended June 30, 2024 and year ended March 31, 2025. n n7.tPursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the year ended March 31, 2025. n n8.tThe Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. n n9.tDuring the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) has acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.). The transaction has been accounted for as an 'asset acquisition' under Ind AS 103. n nThe costs incurred till March 31, 2025 eligible for capitalization are being accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter ended 30 June 2025, additional pre-operating cost of Rs. 55 million eligible for capitalisation has been accumulated under capital work in progress. n n10.tExceptional items: n na.tDuring the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. n nThe sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. n nb.tDuring the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 365 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 79 million and Rs. 147 million is included within tax expense for the respective period/ year. n nc.tDuring the quarter ended June 30, 2024 and year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016. n nd.tBBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. n ne.tDuring the year ended March 31, 2024, one of the subsidiaries of Biocon Biologics Limited (“BBL”) had received Rs. 18,269 million towards working capital under the existing arrangements. BBL had recorded these receivables at fair value of Rs. 10,219 million having regard to the timing and probability of recovery. n nDuring the year ended March 31, 2025, BBL settled Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. n nf.tDuring the year and quarter ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. n ng.tDuring the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. n n11.tThe figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures upto third quarter of the relevant financial year, which were subject to limited review. n n n n n nFor and on behalf of the Board of Directors of Biocon Limited n n n nBangalore, t ttt Kiran Mazumdar-Shaw nAugust 07, 2025ttt tExecutive Chairperson n DIN: 00347229 n n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Generics 6965000000 6965000000
2 Biosimilars 24578000000 24578000000
3 CRDMO 8745000000 8745000000
Total Segment Revenue 40288000000
Less: Inter segment revenue 869000000 869000000
Revenue from operations 39419000000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Generics -670000000 -670000000
2 Biosimilars 960000000 960000000
3 CRDMO 1013000000 1013000000
Total Profit before tax 1303000000
i. Finance cost 0 0
ii. Other Unallocable Expenditure net off Unallocable income 334000000 334000000
Profit before tax 969000000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Generics 79533000000 79533000000
2 Biosimilars 447112000000 447112000000
3 CRDMO 66747000000 66747000000
Total Segment Asset 593392000000 593392000000
Un-allocable Assets 20549000000 20549000000
Net Segment Asset 613941000000 613941000000
4 Segment Liabilities
Segment Liabilities
1 Generics 29318000000 29318000000
2 Biosimilars 224602000000 224602000000
3 CRDMO 18282000000 18282000000
Total Segment Liabilities 272202000000 272202000000
Un-allocable Liabilities 21764000000 21764000000
Net Segment Liabilities 293966000000 293966000000
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) Contract Research, Development, and Manufacturing Organisation (CRDMO) formerly referred to as 'Research Services', in line with Company's current business model.t n nNotes:tttttttttt n n1.tThe unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 07, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. n n2.tThese financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. n n3.tThe consolidated financial results include the financial results of the Company and its subsidiaries as follows: n ni.tSyngene International Limited (‘’Syngene’’) nii.tBiocon Biologics Limited (“BBL”) niii.tBiocon Pharma Limited (“BPL”) niv.tBiocon Academy nv.tBiocon SA nvi.tBiocon SDN. BHD nvii.tBiocon FZ LLC nviii.tBiocon Biologics UK Limited nix.tBiocon Pharma Inc. nx.tBiocon Biologics Healthcare Malaysia SDN. BHD nxi.tBiocon Pharma Ireland Limited nxii.tBiocon Pharma UK Limited nxiii.tBiocon Biosphere Limited nxiv.tBiocon Biologics Inc. nxv.tBiocon Biologics Do Brasil Ltda nxvi.tBiocon Biologics FZ-LLC nxvii.tBiocon Pharma Malta Limited nxviii.tBiocon Pharma Malta I Limited nxix.tSyngene USA Inc. nxx.tSyngene Manufacturing Solutions Limited nxxi.tSyngene Scientific Solutions Limited nxxii.tBiosimilar Collaborations Ireland Limited nxxiii.tBiosimilars Newco Limited nxxiv.tBiocon Biologics Canada Inc. nxxv.tBiocon Biologics Germany GmbH nxxvi.tBiocon Biologics France S.A.S nxxvii.tBiocon Biologics Spain, S.L. nxxviii.tBiocon Biologics Switzerland AG nxxix.tBiocon Biologics Belgium BV nxxx.tBiocon Biologics Finland OY nxxxi.tBiocon Generics Inc. nxxxii.tBiocon Biologics Morocco S.A.R.L.A.U nxxxiii.tBiocon Biologics Greece SINGLE MEMBER P.C nxxxiv.tBiocon Biologics South Africa (PTY) Ltd nxxxv.tBiocon Biologics (Thailand) Co. Ltd nxxxvi.tBiocon Biologics Philippines Inc nxxxvii.tBiocon Biologics Italy S.R.L nxxxviii.tBiocon Biologics Croatia LLC nxxxix.tBiocon Biologics Global PLC n nBiocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. n n4.tDuring the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). n nOut of the above proceeds, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) of face value of Rs. 1,00,00,000 issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million. n n5.tOn May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- with record date of July 4, 2025. The proposed dividend is subject to the approval of the shareholders of the Company in its Annual General Meeting. n n6.tIn April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the quarter ended June 30, 2024 and year ended March 31, 2025. n n7.tPursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the year ended March 31, 2025. n n8.tThe Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. n n9.tDuring the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) has acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.). The transaction has been accounted for as an 'asset acquisition' under Ind AS 103. n nThe costs incurred till March 31, 2025 eligible for capitalization are being accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter ended 30 June 2025, additional pre-operating cost of Rs. 55 million eligible for capitalisation has been accumulated under capital work in progress. n n10.tExceptional items: n na.tDuring the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. n nThe sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. n nb.tDuring the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 365 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 79 million and Rs. 147 million is included within tax expense for the respective period/ year. n nc.tDuring the quarter ended June 30, 2024 and year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016. n nd.tBBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. n ne.tDuring the year ended March 31, 2024, one of the subsidiaries of Biocon Biologics Limited (“BBL”) had received Rs. 18,269 million towards working capital under the existing arrangements. BBL had recorded these receivables at fair value of Rs. 10,219 million having regard to the timing and probability of recovery. n nDuring the year ended March 31, 2025, BBL settled Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. n nf.tDuring the year and quarter ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. n ng.tDuring the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. n n11.tThe figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures upto third quarter of the relevant financial year, which were subject to limited review. n n n n n nFor and on behalf of the Board of Directors of Biocon Limited n n n nBangalore, t ttt Kiran Mazumdar-Shaw nAugust 07, 2025ttt tExecutive Chairperson n DIN: 00347229 n n



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -1838000000 -1838000000
Total Amount of items that will not be reclassified to profit and loss -1838000000
2 Income tax relating to items that will not be reclassified to profit or loss -95000000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss -586000000 -586000000
Total Amount of items that will be reclassified to profit and loss -586000000
4 Income tax relating to items that will be reclassified to profit or loss -274000000
5 Total Other comprehensive income -2055000000